Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide

Overview of attention for article published in Clinical Genitourinary Cancer, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#16 of 1,061)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 3 news outlets

twitter: 11 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 2 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Hospitalization Risk Higher With Abiraterone Than With Enzalutamide

Cancer Therapy Advisor, 25 Jul 2023

Patients with metastatic prostate cancer treated with abiraterone have a higher rate of hospitalization than those treated with…

Hospitalization Risk Higher With Abiraterone vs Enzalutamide

MPR, 24 Jul 2023

Men with metastatic prostate cancer treated with abiraterone have a higher rate of hospitalization compared with those treated…

Hospitalization Risk Higher With Abiraterone vs Enzalutamide

Renal & Urology News, 21 Jul 2023

Men with metastatic prostate cancer treated with abiraterone have a higher rate of hospitalization compared with those treated…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.